GLP-1s for PCOS insulin resistance: helpful tool, not a cure

What did @drnighatarif actually say?

Dr. Arif's core argument is measured: GLP-1 receptor agonists like semaglutide and tirzepatide show promise for insulin-resistant PCOS, particularly for weight management and reproductive outcomes, but the data is thin and long-term safety is unknown. She cited the International Evidence-Based Guidelines for PCOS and a 2025 meta-analysis of randomized controlled trials. She was also careful to note these drugs are used "off-license" for PCOS in the UK and are not available through the NHS for this indication. Her conclusion was essentially: interesting signal, not enough data, don't call it a cure.

She also made an observational point worth flagging: several of her PCOS patients on GLP-1s lost weight and became pregnant. That's anecdote, not evidence, and she didn't frame it as anything more than that, which is fair.

Does the science back this up?

Broadly, yes. The 2025 meta-analysis she references aligns with what's currently published. A 2024 meta-analysis by Jensterle et al. in the journal Reproductive Biology and Endocrinology found GLP-1 receptor agonists significantly reduced BMI, fasting insulin, and testosterone levels in women with PCOS compared to controls, but the trials were small and short. The International PCOS Guideline Network (Teede et al., 2023, Human Reproduction) does recommend anti-obesity agents in PCOS only within research settings for reproductive outcomes, exactly as she stated.

Her 70% insulin resistance prevalence figure is in the right ballpark. Published estimates range from 50% to 80% depending on the diagnostic criteria used (Diamanti-Kandarakis and Dunaif, 2012, Endocrine Reviews). Saying "about 70%" is a reasonable middle estimate, not a fabrication.

What did they get wrong (or right)?

She got the headline right: GLP-1s are not a cure for PCOS. Full stop. PCOS is a complex endocrine condition with genetic, metabolic, and reproductive dimensions. Weight loss, even significant weight loss, does not resolve the underlying hormonal dysregulation in most patients. She said as much, which deserves credit.

What she could have done better: she mentioned patients "becoming pregnant" after starting GLP-1s without flagging that semaglutide and tirzepatide carry a pregnancy warning. Both drugs should be discontinued at least two months before attempting conception per manufacturer guidance, and there are no adequate human pregnancy safety studies. The FDA labels for Ozempic and Wegovy explicitly note potential fetal harm based on animal data. Listing pregnancy as a positive outcome without this context is a meaningful omission for a video targeting people with a fertility-related condition.

She also described the 2025 meta-analysis as showing "promise from the few trials we've got," which is honest. But she didn't mention that most existing RCTs on GLP-1s in PCOS use liraglutide, not semaglutide or tirzepatide, so direct extrapolation to the newer drugs she named has limits.

What should you actually know?

If you have PCOS and you're thinking about GLP-1 therapy, here's what the current evidence actually supports. GLP-1 receptor agonists can produce meaningful weight loss and improve metabolic markers like fasting insulin and androgen levels in women with PCOS. That's real. But none of these drugs are approved specifically for PCOS anywhere, meaning use is off-label and should involve a specialist who knows your full picture.

The fertility question is genuinely complicated. Weight loss through any means, including GLP-1s, can restore ovulatory function in women with obesity-related PCOS. But GLP-1 drugs must be stopped before conception, and no one knows yet whether the metabolic improvements outlast the drug once it's discontinued. That's not a minor gap. For a lifelong condition in people of reproductive age, it's one of the most important questions in the field and it remains unanswered.

• Do not use GLP-1s during pregnancy or when actively trying to conceive without direct specialist guidance.
• These drugs address metabolic symptoms of PCOS, not its root cause.
• Long-term data on PCOS-specific outcomes simply does not exist yet for semaglutide or tirzepatide.
• NHS eligibility criteria for GLP-1s are based on BMI and comorbidities, not PCOS diagnosis.